CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

Core Insights - CERo Therapeutics has initiated dosing of the second patient in its Phase 1 clinical trial for CER-1236, targeting acute myeloid leukemia (AML) [1][2] - The first patient showed no dose-limiting toxicities during the observation period, with a significant 20.8-fold expansion of infused cells observed at 14 days post-infusion [2][3] - The trial aims to evaluate the safety and preliminary efficacy of CER-1236, with primary outcomes including adverse events and overall response rates [3][4] Company Overview - CERo Therapeutics is focused on developing next-generation engineered T cell therapeutics, specifically targeting cancer through a novel approach that integrates innate and adaptive immunity [5] - The company’s lead product candidate, CER-1236, is designed to utilize phagocytic mechanisms to enhance the elimination of tumors, potentially offering broader therapeutic applications than current CAR-T therapies [5]